Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02887677|
Recruitment Status : Recruiting
First Posted : September 2, 2016
Last Update Posted : June 1, 2018
This study is designed to test the hypothesis that the treatment-induced reductions in the ambulatory aortic pressure are more pronounced in the group of dapagliflozin than in the group of placebo.
It is a 12 week, double-blind, randomized, placebo-controlled clinical trial of dapagliflozin versus placebo in 160 adult patients with type 2 diabetes mellitus (DM). It will be conducted in three centers.
Potentially eligible patients will be asked to provide written informed consent (Screening Visit). Patients, who fulfill the inclusion and exclusion criteria, will be asked to visit the sites one week (Visit 1 - V1) after the screening visit. On Visit 2 (V2) all eligible patients will be randomized to one of the two treatment arms and will continue with the next visits as appropriate (Visit 3, Telephone Visit 1, Visit 4-end of study).
Aortic blood pressure (BP) and arterial stiffness parameters will be measured as indicated by the protocol in V1 and V3 with the Mobil-O-Graph monitor.
Blood samples will be collected as indicated by the protocol in Screening Visit for the measurement of glycated hemoglobin (HbA1c), creatinine and liver function parameters. In addition, blood samples will be collected in V1 and V3 for routine hematological and biochemical tests including creatinine, fasting glucose, HbA1c, lipid profile and liver function parameters.
Urine samples will be collected as indicated by the protocol in V1 and V3 for the measurement of albumin to creatinine ratio.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus||Drug: Dapagliflozin Drug: Placebo||Phase 4|
Screening visit: Potentially eligible patients will be asked to provide written informed consent. The investigators will record full medical history, clinical examination, demographic characteristics, electrocardiogram (ECG), body weight, height, body mass index (BMI) and waist perimeter. Office blood pressure (BP) will be measured by the physicians three times using a mercury sphygmomanometer [cuffs will be placed at the level of brachial artery and a three minute interval will intercept each measurement, following 10 minutes of rest in the seated position (the cuff will cover at least 80% of the brachial circumference and 2/3 of the brachial length.)]. The investigators will also collect blood samples to determine glycated hemoglobin (HbA1C), creatinine, glomerular filtration rate (GFR) and liver function.
Visit 1 (V1): Patients, who fulfill the inclusion and exclusion criteria, will be asked to visit the sites 1 week after the screening visit (+/-2 days), following a 12-hour fast. Three measurements of office BP at the level of brachial artery, with a three minutes interval between each measurement, will be performed with the use of a mercury sphygmomanometer, after 10 minutes-rest in the sitting posture (cuff with bladder size encircling at least 80% of arm circumference and covering two thirds of arm length). After that, venous blood specimens and a spot urine specimen will be collected for relevant blood tests and albumin/creatinine ratio (ACR) respectively. Subsequently, the Mobil-O-Graph monitor with a cuff of appropriate size will be fitted and the BP recording will be initiated for 24 hours. The device will be programmed to collect data every 20 minutes, except for 23:00 to 07:00 (data collection every 30 minutes).
Visit 2 (V2): An appointment will be scheduled the following day for the patient to drop-off the Mobil-O-Graph device. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group and will start receiving the drug regimen the same day. Moreover, all patients will receive dietary and lifestyle advice commencing from this visit.
Telephone Visit 1 (ΤV1): A telephone visit (TV1) will be scheduled 6 weeks after V2 (+/-2 days). Patient history will be obtained, emphasizing on possible adverse events during the previous 6 weeks. Home blood glucose levels, if available, would be also discussed.
Visit 3 (V3): Visit 3 will be scheduled 6 weeks after telephone visit 1 (TV1) (+/-2 days). The following parameters will be determined: medical history of the last weeks, clinical examination (including three brachial BP measurements with a mercury sphygmomanometer as mentioned before), venous blood specimen collection (under 12-hour fast) and the initiation of 24-hour ambulatory blood pressure monitoring (ABPM) (Mobil-O-Graph device). The patients will also provide a spot urine specimen for ACR evaluation.
Visit 4 (V4): Visit 4 will be scheduled 1 day after visit 3. Patients will drop-off the Mobil-O-Graph device.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes|
|Actual Study Start Date :||October 2016|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||December 2019|
Active Comparator: Dapagliflozin
Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
Other Name: Forxiga
Placebo Comparator: Placebo
Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
- Ambulatory systolic aortic pressure [ Time Frame: 12 weeks ]
- Ambulatory aortic (central) diastolic blood pressure (DBP) [ Time Frame: 12 weeks ]
- Ambulatory brachial systolic blood pressure (SBP) and DBP [ Time Frame: 12 weeks ]
- Ambulatory augmentation index (AIx) [ Time Frame: 12 weeks ]
- Ambulatory pulse wave velocity (PWV) [ Time Frame: 12 weeks ]
- Office brachial SBP and DBP [ Time Frame: 12 weeks ]
- Albumin/creatinine ratio (ACR) [ Time Frame: 12 weeks ]
- Lipid profile (Total-Cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides) [ Time Frame: 12 weeks ]
- HbA1c [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02887677
|Contact: Asterios Karagiannisfirstname.lastname@example.org|
|Thessaloniki, Greece, 54621|
|Contact: Kalliopi Kotsa +306932045201 email@example.com|
|Sub-Investigator: Elena Aggeloudi|
|Thessaloniki, Greece, 54642|
|Contact: Asterios Karagiannis +306972011271 firstname.lastname@example.org|
|Sub-Investigator: Eirini Papadopoulou|
|Sub-Investigator: Athanasios Binas|
|Sub-Investigator: Alexia Piperidou|
|Thessaloniki, Greece, 56429|
|Contact: Glyceria Tzatzagou 2313323165 email@example.com|
|Sub-Investigator: Despoina Kosmidou|
|Sub-Investigator: Eleonora Kella|
|Principal Investigator:||Pantelis Sarafidis||Aristotle University Of Thessaloniki|